Skip to contentA
Autolus Therapeutics plc
A
AUTLAutolus Therapeutics plc Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$29.00K$29.00Kderivedno prior Q4 2023 on file Net Income-$27.61M-$27.61MderivedN/M vs Q4 2023 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Autolus Therapeutics plc · CIK 1730463 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$75,864,000N/M Operating Cash Flowderived-$37,934,000N/M Free Cash Flowderived-$49,046,000N/M Margins · derivedOperating margin-261600.0%
Net margin-95193.1%
ended Dec 31, 2024 · filed Mar 20, 2025 · 79 d after period end